Pharma Services Explained: Hub, Specialty Pharmacy, FRM, and How They Fit Together

TL;DR

The pharma commercial services stack is the set of outsourced functions a manufacturer buys to move a specialty drug from an FDA approval to a patient on therapy. Six core components do most of the work: hub services (the central case-management layer), specialty pharmacies (who actually dispense), field reimbursement managers (office-based access troubleshooters), copay and financial assistance programs (cost mitigation for insured patients and free drug for the uninsured), market access consulting (pricing, payer strategy, contracting), and real-world data and patient journey analytics (who got the drug, who dropped off, why). Buyers routinely confuse a hub with a specialty pharmacy because both talk to patients, both handle insurance, and some vendors offer both. They are not the same. A hub coordinates access. An SP dispenses product. The rest of this guide defines each layer, explains how they connect across a patient’s journey, and names the vendors that sit in each box.

---

Master Comparison: The 5 Core Pharma Services Roles

Dimension	Hub Services	Specialty Pharmacy (SP)	Field Reimbursement (FRM)	Copay Processor	Market Access Consultant
Primary function	Case management of patient access end-to-end	Dispense specialty drug, counsel patient, ship	In-person access support at provider offices	Adjudicate copay card as secondary claim at POS	Pricing, payer, and contracting strategy pre-launch
Revenue model	Per-patient-per-month or FTE fee paid by manufacturer	Dispensing fee + drug margin paid by payer	Fully loaded FTE paid by manufacturer	Per-redemption transaction fee paid by manufacturer	Project fee or retainer paid by manufacturer
Typical cost	Direct manufacturer program fee, usually scoped by patient volume and staffing model	Not a direct pharma cost; SP earns from payer	Direct manufacturer field-team expense	Per-redemption or platform fee paid by manufacturer	Project fee or retainer paid by manufacturer
When you need it	At launch for any PA-required specialty drug	At launch for any limited distribution product	At launch, especially buy-and-bill and oncology	Any drug with a commercial copay program	Pre-launch access strategy and payer planning
Who owns the relationship	Manufacturer contracts directly	Manufacturer designates network; payer mandates often override	Manufacturer employs or contracts via CSO	Manufacturer contracts; hub may coordinate	Manufacturer’s market access team
Example vendors	ConnectiveRx, EVERSANA, AssistRx, CareMetx, Lash Group, Valeris, CareTria, Conduent, Phil	Accredo, CVS Specialty Pharmacy, OptumRx Specialty Pharmacy, PANTHERx Rare, Orsini	EVERSANA, Inizio Engage, bundled via CareMetx	ConnectiveRx, CareMetx, AssistRx	Trinity Life Sciences, IQVIA

The row that trips up most buyers is the revenue model row. Hub services are a direct line item in a brand’s P&L. Specialty pharmacies are not. An SP makes its margin from the drug spread and the payer’s dispensing fee. That economic distinction is why an SP’s incentives can pull away from the manufacturer’s on issues like channel exclusivity, patient steering, and data access.

---

1. Hub Services

What it is

A hub is the centralized operations layer a manufacturer contracts to coordinate every step of patient access for a specialty drug. The term “hub” reflects its role as the central node connecting five parties: manufacturer, prescriber, payer, pharmacy, and patient. In practical terms, it is a combination of call-center agents, a case-management technology platform, nurse support, and analytics.

What it does

• Enrolls patients via fax form, provider portal, EHR integration, or SP referral
• Runs benefits investigation: verifies coverage, determines medical vs pharmacy benefit, identifies PA requirements and patient out-of-pocket cost
• Supports prior authorization: pre-populates forms, tracks status, facilitates peer-to-peer reviews and appeals
• Triages patients to financial assistance: copay cards for commercial, foundation grants for Medicare, PAP for uninsured, bridge programs while PA is pending
• Coordinates pharmacy handoff: routes Rx to the right SP based on payer mandate and manufacturer limited distribution network
• Runs adherence programs: refill reminders, nurse educator touchpoints, abandonment prediction

How it’s priced

Hub pricing is normally quoted as per-patient-per-month fees for variable-volume services, loaded FTE fees for dedicated staff, or a blended model. Buyers should force vendors to separate implementation, steady-state case management, nurse support, technology, reporting, and change-order economics in the RFP rather than comparing a single headline fee.

Example vendors

• ConnectiveRx: Kohlberg-backed, strong copay and hub technology.
• EVERSANA: End-to-end commercialization platform; EVERSANA DIRECT combines hub, affordability, specialty pharmacy, and 3PL in one stack.
• AssistRx: iAssist platform, strong in EHR integrations and electronic services.
• Lash Group: Largest hub operator by program count; part of Cencora (formerly AmerisourceBergen).
• CareMetx: Digital Hub platform with hub, affordability, and field-support workflows.

For a deeper operational treatment, see Hub Services Buyer’s Guide and the Hub RFP framework.

---

2. Specialty Pharmacy (SP)

What it is

A specialty pharmacy is a licensed pharmacy that dispenses high-cost, high-complexity medications requiring clinical counseling, cold-chain logistics, or special handling. Specialty pharmacies differ from retail pharmacies in that they operate centralized fulfillment (not storefronts), ship directly to patients, employ clinical pharmacists who counsel patients on specialty therapies, and coordinate with payers on PA and copay adjudication at point of sale.

What it does

• Receives a prescription from the prescriber (often routed by the hub)
• Confirms PA is on file and performs insurance reverification
• Counsels the patient by phone or video on administration, side effects, and storage
• Adjudicates copay at POS, including applying any copay card as secondary coverage
• Ships drug via refrigerated courier with signature confirmation
• Schedules refills and monitors adherence

How it’s priced

SPs earn from the payer, not the manufacturer. Revenue comes from the spread between acquisition cost and negotiated reimbursement, plus any dispensing fees in the payer contract. The manufacturer’s leverage is the limited distribution network (LDN): only SPs in the manufacturer’s network can dispense the product, so SPs compete for network slots by offering better data, faster time to therapy, or therapeutic expertise.

Example vendors

• Accredo: The largest specialty pharmacy in the U.S., owned by Evernorth (Cigna/Express Scripts).
• CVS Specialty Pharmacy: The SP arm of CVS Health, integrated with Caremark PBM.
• OptumRx Specialty Pharmacy: UnitedHealth Group’s SP, integrated with OptumRx.
• PANTHERx Rare: Rare and ultra-orphan specialist, smaller network but deep therapeutic expertise.
• Orsini: Rare disease and gene therapy focus, high-touch model.

For the payer-owned SP landscape, see Big 3 PBM Specialty Pharmacies and Top Specialty Pharmacies for Pharma Manufacturers.

---

3. Field Reimbursement Manager (FRM)

What it is

A Field Reimbursement Manager is a manufacturer-deployed field specialist who visits prescriber offices, infusion centers, and academic medical centers to help office staff navigate reimbursement, coding, and payer policy for a specific specialty product. FRMs sit at the intersection of market access strategy and hub operations. They are the in-person, decentralized extension of the hub.

Critically, FRMs are not sales reps. The compliance boundary is strict: FRMs do not discuss drug efficacy, safety, or clinical information. Violating that line exposes the manufacturer to Anti-Kickback Statute and False Claims Act risk.

What it does

• Trains office staff on PA submission workflows, documentation standards, and payer-specific forms
• Advises on correct J-codes, HCPCS codes, and ICD-10 diagnosis codes for buy-and-bill products
• Interprets payer medical policies, step therapy requirements, and site-of-care restrictions
• Educates office staff on the appeals process and peer-to-peer review preparation
• Feeds intelligence back to the hub on systemic access barriers at key accounts

How it’s priced

FRMs are usually budgeted as fully loaded field FTEs, with cost varying by geography, therapeutic complexity, travel burden, and whether the role is in-house, dedicated outsourced, or shared through a contract commercial organization. Buyers should compare salary, incentive compensation, travel, management overhead, training, CRM access, and replacement SLAs rather than asking only for a blended FTE rate.

For public planning, Rx Almanac treats FRM cost as a component model rather than a fixed market quote. Current public salary benchmarks put U.S. field reimbursement manager base pay around the mid-$100,000s (Salary.com), and BLS employer-cost data shows benefits add a material load above wages (BLS Employer Costs for Employee Compensation). Travel, tools, training, management span, and compliance monitoring then determine whether the loaded field expense fits the product’s access burden.

Example vendors

FRM capability is most often bundled inside a broader commercialization platform rather than bought standalone:

• EVERSANA: Integrates FRMs into its end-to-end commercialization stack with data feedback loops between field and hub.
• CareMetx: FRM as an extension of the Digital Hub platform.
• Inizio Engage: Dedicated contract commercial organization with FRM, field-force, and patient-support deployment capacity.

Oncology and rare disease FRMs command the highest cost premium because of the depth of medical-benefit billing, NCCN compendia, and site-of-care expertise required.

---

4. Copay and Financial Assistance Programs

What it is

Financial assistance is the umbrella term for the programs a manufacturer funds to reduce a patient’s out-of-pocket cost (for insured patients) or provide the drug free (for the uninsured or underinsured). The mechanics split across three channels:

• Copay assistance (commercial): A manufacturer-funded copay card or e-voucher reduces the commercially insured patient’s copay at the pharmacy under product-specific program rules.
• Patient assistance programs (PAP): Free drug for uninsured or underinsured patients under eligibility rules set by the manufacturer and program administrator.
• Foundation referrals (Medicare): Manufacturers cannot provide direct copay assistance to Medicare patients under the Anti-Kickback Statute, so Medicare patients are referred to independent charitable foundations (PAN Foundation, HealthWell Foundation, disease-specific foundations). HHS OIG describes anti-kickback risk around manufacturer copayment coupons for federal health care program beneficiaries.

What a copay processor does

A copay processor is the specialized claims engine that adjudicates the copay card as secondary insurance at the point of sale. When a patient fills at a specialty pharmacy, the primary insurance adjudicates first, then the copay card adjudicates as secondary and covers most of the patient’s remaining responsibility. Copay processors also detect and respond to copay accumulators and maximizers (plan designs that divert the manufacturer’s copay contribution away from the patient’s deductible).

How it’s priced

Copay processor fees are usually quoted per redemption or bundled into a broader hub / affordability contract. PAP administration is often bundled into the hub contract. Buyers should price commercial copay, accumulator detection, PAP screening, foundation routing, and reporting as separate workstreams even when one vendor runs the whole affordability layer.

Example vendors

• ConnectiveRx: Large-scale copay and affordability platform often evaluated alongside hub programs.
• CareMetx: Copay administration integrated with the Digital Hub.
• AssistRx: Copay services bundled within the iAssist platform.

For head-to-head vendor pricing and accumulator handling, see Copay Processors Comparison.

---

5. Market Access / Managed Markets

What it is

Market access is the strategic function (and set of external consultants) that designs how a drug will be priced, covered, and paid for. It starts before launch and extends into ongoing payer engagement post-launch. Market access is distinct from hub services: the hub runs patient-level operations, market access negotiates with payers.

What it does

• Pricing strategy and gross-to-net modeling
• Payer value-proposition development and AMCP dossier production
• Formulary and PBM contracting strategy
• Rebate and value-based contract design
• Real-world evidence planning to support payer negotiations
• Post-launch payer engagement and account management

How it’s priced

Market access consulting is typically project-based or retained. Pre-launch scope often includes value proposition, AMCP dossier, payer research, and pricing strategy; ongoing managed-markets field teams are usually staffed by the manufacturer or a dedicated commercial partner. Compare deliverables, payer-research depth, contracting analytics, and account-team support rather than headline project fees.

Example vendors

• Trinity Life Sciences: Commercial strategy and pricing/access consulting.
• IQVIA: Market access consulting alongside data and analytics.
• Charles River Associates, Putnam, ClearView, Simon-Kucher: Other major players in pricing and access strategy.

For a deeper treatment of the consulting firms, see Market Access Consulting.

---

6. Real-World Data and Patient Journey Analytics

What it is

Real-world data (RWD) and patient journey analytics is the layer that measures what actually happens once a drug is launched: who got prescribed, who got PA-approved, who filled, who stayed on therapy, and where the funnel leaks. This category is often overlooked in the services stack because it is sometimes bundled into hub reporting, but the most sophisticated brands buy it separately.

What it does

• Patient-level dashboards spanning enrollment to persistence
• Payer-level analysis: approval rates, turnaround times, denial reasons by payer
• Prescriber-level analysis: prescribing patterns, geographic concentration
• Abandonment and discontinuation prediction
• Integration with hub data, SP dispensing data, and claims data

How it’s priced

Hub-reporting analytics are typically bundled. Standalone RWD subscriptions and claims-data platforms are priced by data scope, longitudinal depth, permitted use, refresh cadence, and licensing restrictions.

Example vendors

• IQVIA: Longitudinal patient data, claims data, and commercial analytics.
• CoverMyMeds: Dominant in ePA data with expanding hub-adjacent analytics.
• Claritas Rx, Komodo Health, Symphony Health: Specialty patient journey and RWD platforms.

---

How They Fit Together: One Patient’s Journey

Walk a single patient through a specialty drug launch and it becomes clear why these layers exist and where they hand off.

1. Prescriber writes Rx for a specialty biologic. The prescription is routed to the manufacturer’s hub via fax, provider portal, or EHR integration.
2. The hub enrolls the patient and begins benefits investigation, discovering that the patient’s commercial payer requires prior authorization.
3. The hub pre-populates the PA form and returns it to the prescriber’s office. The office submits. The payer denies on step therapy grounds.
4. An FRM visits the prescriber’s office, identifies that the step therapy exemption was improperly documented, and coaches the office through a successful appeal.
5. PA approved. In this illustrative scenario, the patient still faces meaningful out-of-pocket exposure. The hub enrolls the patient in the manufacturer’s copay card program.
6. The copay processor stands ready to adjudicate as secondary insurance at point of sale.
7. The hub routes the Rx to a specialty pharmacy in the manufacturer’s limited distribution network. The payer mandates their own SP, so there’s a routing negotiation; patient is routed to the payer’s SP.
8. The specialty pharmacy performs clinical intake, counsels the patient, and ships. At adjudication, the primary payer pays first; the copay card pays secondary down to $0.
9. Thirty days later, the hub calls the patient for adherence check-in. The patient reports side effects. A hub nurse educator coordinates with the prescriber’s office.
10. Twelve months later, at insurance re-verification, the hub catches a formulary change and initiates re-authorization before therapy is interrupted.
11. Throughout, the market access team is engaging the payer on rebate contracts and formulary tier positioning. RWD analytics track the patient anonymously alongside a cohort, producing the data that market access uses in its next negotiation.

Every layer shows up. None of them can do another’s job well.

---

Common Confusions

Hub vs Specialty Pharmacy

Both talk to patients. Both coordinate with payers. Both influence time to fill. They are not the same.

• A hub never touches product. It is case management, not dispensing.
• A specialty pharmacy never bills the manufacturer directly for services. It earns through payer reimbursement.
• A hub is an operating expense on the brand P&L. An SP is not.
• One patient typically uses both: the hub coordinates access, the SP dispenses.

Vendor overlap blurs the line. EVERSANA operates both a hub and EVERSANA DIRECT specialty pharmacy. ConnectiveRx is also evaluated across hub, copay, and dispensing-adjacent workflows. Even when one vendor does both, the functions are priced and operated separately.

Hub vs FRM

Both help with prior authorization. Both are paid by the manufacturer.

• A hub is centralized and reactive: a call-center case manager processes PA paperwork flowing in from many accounts.
• An FRM is decentralized and proactive: a field specialist visits one office to prevent PA failures before they happen.

The rule of thumb: if the access barrier shows up at one large account (an academic medical center with 40 prescribers), an FRM is the tool. If the barrier is distributed across thousands of low-volume prescribers, the hub is the tool. Most launches need both.

Copay Processor vs Hub

Both deal with financial assistance. One is transaction processing, the other is program orchestration.

• A copay processor is a specialized claims adjudication engine. It runs for milliseconds at the pharmacy counter as a secondary claim.
• A hub owns enrollment into the program, patient eligibility screening, accumulator detection strategy, and coordination with the PAP for patients who don’t qualify for copay.

ConnectiveRx, CareMetx, and AssistRx operate both as hubs and as copay processors. Standalone copay processors exist but are increasingly rare; the market has consolidated around hub-integrated offerings.

---

When You Need Each One: Biotech Archetypes

Rare disease and ultra-orphan launches

• Hub: Yes, but smaller and more bespoke. Some biotechs build in-house patient services for very small populations instead of outsourcing the full hub.
• Specialty pharmacy: Yes. Usually a narrow LDN of 1 to 3 rare-disease specialists like PANTHERx Rare or Orsini. Drug Channels’ LDD network analysis shows 68% of LDD products use 1-4 pharmacies.
• FRM: Small, targeted team covering geographically dispersed KOL accounts. Often combined with patient access coordinator functions.
• Copay: Yes, but low redemption volume; the program may be bundled with the hub.
• Market access: Critical. Ultra-orphan pricing strategy drives the business case.
• RWD: Modest; sample sizes are too small for traditional claims analytics.

Oncology biologic (buy-and-bill)

• Hub: Yes, full scope. Buy-and-bill products generate more calls per patient than pharmacy-dispensed products.
• Specialty pharmacy: Less central; many oncology biologics are physician-administered and flow through specialty distributors, not SPs. White-bag and clear-bag dynamics complicate this.
• FRM: Yes, heavily. Oncology is the highest-demand FRM specialty because of medical-benefit billing, NCCN compendia, and site-of-care economics.
• Copay: Yes, including medical-benefit copay, which requires specific processor capability.
• Market access: Complex. NCCN compendia listings and payer medical policy drive access.
• RWD: Rich. Claims and EMR data support commercial and medical affairs use cases.

Autoimmune (broad specialty)

• Hub: Yes, at scale. Broad specialty launches need larger case-management capacity and tighter automation than rare-disease programs.
• Specialty pharmacy: Broad LDN. Payer mandates frequently override manufacturer preference, so SP mix is diverse. PBM-owned SPs (Accredo, CVS Specialty, Optum Specialty) capture most volume.
• FRM: Larger team covering high-volume rheumatology and gastroenterology accounts.
• Copay: Critical. Accumulator and maximizer exposure is highest in autoimmune.
• Market access: Biosimilar pressure and step therapy drive strategy.
• RWD: Mature. Standard claims and hub data.

Primary-care specialty (e.g., diabetes biologic, migraine CGRP)

• Hub: Smaller-scope hub or hybrid. Lower PA burden means the hub focuses on copay and adherence more than access.
• Specialty pharmacy: Often retail-dispensed or mixed channel. Some are through SP, some through retail with step edits.
• FRM: Smaller team, concentrated on high-writers.
• Copay: Critical at scale. Volume drives per-redemption economics.
• Market access: Formulary positioning and prior-auth rate negotiation are the wars.
• RWD: Mature; leverage retail pharmacy claims data.

---

Getting the Stack Right

For a biotech evaluating the services stack before launch, the default mistake is to over-focus on the hub and under-invest in everything else. A better framing:

1. Market access first: before you run an RFP for a hub, know your pricing strategy, payer value proposition, and target formulary positioning. These drive hub requirements.
2. Hub RFP next: use a structured framework. See the Hub RFP framework for the evaluation questions.
3. SP network design concurrent with hub: the hub coordinates with SPs, so the two must be designed together.
4. FRM team build before launch: field teams need time to recruit, train, and deploy.
5. Copay program design with the hub: most buyers now purchase copay as part of the hub contract, which simplifies coordination but removes leverage on unit economics.
6. RWD contracts post-launch: wait until you know what data you actually need; pre-launch RWD subscriptions often go unused.

The services stack is not a menu of independent items. Every component hands off to at least two others. The biotechs that treat it as a system, not a shopping list, get meaningfully shorter time to therapy, higher PA approval rates, and lower per-patient cost to serve.

---

Related Reading

• Hub Services Buyer’s Guide
• Hub Services Platforms
• Hub RFP Framework
• Hub Services Market Analysis
• Big 3 PBM Specialty Pharmacies
• Top Specialty Pharmacies for Pharma Manufacturers
• AI Prior Auth Vendors
• Market Access Consulting
• Copay Processors Comparison